Caplin Point Lab

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE475E01026
  • NSEID: CAPLIPOINT
  • BSEID: 524742
INR
1,560.90
-34.8 (-2.18%)
BSENSE

Mar 27

BSE+NSE Vol: 1.12 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 640544,
    "name": "Caplin Point Lab",
    "stock_name": "Caplin Point Lab",
    "full_name": "Caplin Point Laboratories Ltd",
    "name_url": "stocks-analysis/caplin-point-lab",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,560.90",
    "chg": -34.8,
    "chgp": "-2.18%",
    "dir": -1,
    "prev_price": "1,595.70",
    "mcapval": "11,982.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524742,
    "symbol": "CAPLIPOINT",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE475E01026",
    "curr_date": "Mar 27",
    "curr_time": "",
    "bse_nse_vol": "1.12 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 27, 2026",
    "traded_date_str": "2026 03 27",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/caplin-point-lab-640544-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Caplin Point Laboratories Ltd Falls to 52-Week Low of Rs 1546.85 as Sell-Off Deepens",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/caplin-point-laboratories-ltd-stock-hits-52-week-low-amid-market-downturn-3920328",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CaplinPointLabo_priceRelatedfactors_3920328.png",
        "date": "2026-03-27 15:50:03",
        "description": ""
      },
      {
        "title": "Why is Caplin Point Laboratories Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-caplin-point-laboratories-ltd-fallingrising-3908861",
        "imagepath": "",
        "date": "2026-03-24 01:31:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Caplin Point Laboratories has been under pressure in the short term, with the stock losing 4.73% over the past week and 10.01% in the last month. Year-to-date, the stock has declined by 15.32%, slightly underperforming the benchmark Sensex, which fell 14.70% in the same period. Over the last year, the stock’s performance has been particularly weak, registering a 22.64% loss compared to the Sensex’s 5.47% decline. Despite this, the company’s longer-term returns remain impressive, with gains of 158.97% over three years and 264.20% over five years, significantly outpacing the benchmark indices.</p>\n<p>On the day of the decline, the stock traded close to its 52-week low, just 0.52% above the lowest price of ₹1,551.05. Intraday, it touched ..."
      },
      {
        "title": "Caplin Point Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3896278",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CaplinPointLabo_mojoScore_3896278.png",
        "date": "2026-03-17 10:10:32",
        "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 March 2026, providing investors with an up-to-date view of the company's performance and outlook."
      },
      {
        "title": "Caplin Point Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3875590",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/CaplinPointLabo_mojoScore_3875590.png",
        "date": "2026-03-06 10:10:44",
        "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Caplin Point Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3850562",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_mojoScore_3850562.png",
        "date": "2026-02-23 10:10:51",
        "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with an up-to-date view of the company’s performance and outlook."
      },
      {
        "title": "Caplin Point Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3850542",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_mojoScore_3850542.png",
        "date": "2026-02-22 10:10:29",
        "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Caplin Point Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/caplin-point-laboratories-ltd-is-rated-sell-3832619",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_mojoScore_3832619.png",
        "date": "2026-02-11 10:11:06",
        "description": "Caplin Point Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 25 November 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Caplin Point Laboratories Ltd Faces Bearish Technical Shift Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/caplin-point-laboratories-ltd-faces-bearish-technical-shift-amid-market-volatility-3827827",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/CaplinPointLabo_technicaldot_3827827.png",
        "date": "2026-02-09 08:01:24",
        "description": "Caplin Point Laboratories Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend. The stock’s recent decline of 4.29% to ₹1,820.00, coupled with deteriorating moving averages and bearish MACD readings, suggests mounting pressure on the pharmaceutical firm’s near-term outlook."
      },
      {
        "title": "Caplin Point Laboratories Gains 2.70%: Mixed Signals Amid Record Quarterly Results",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/caplin-point-laboratories-gains-270-mixed-signals-amid-record-quarterly-results-3826471",
        "imagepath": "",
        "date": "2026-02-07 16:07:14",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Feb:</strong> Stock opens week at Rs.1,799.60, rising 1.23% despite Sensex decline</p>\n                    <p><strong>4 Feb:</strong> Technical momentum shift noted amid mixed market signals</p>\n                    <p><strong>5 Feb:</strong> Q3 FY26 results reveal strong profit growth but valuation concerns</p>\n                    <p><strong>6 Feb:</strong> Mixed quarterly performance reported amid margin pressure, stock dips 3.99%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,777.75</div></div>\n                    <div class=\"stat-item\"><div class..."
      }
    ],
    "total": 590,
    "sid": "640544",
    "stock_news_url": "https://www.marketsmojo.com/news/caplin-point-laboratories-640544"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "13-Mar-2026",
      "details": "Press release regarding receipt of final approval by our subsidiary Caplin Steriles Limited from USFDA for the Potassium Phosphates Injection USP",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Cessation",
      "datetime": "03-Mar-2026",
      "details": "Cessation of Dr. C K Gariyali as an Independent Director of the Company with effect from March 3 2026.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "28-Feb-2026",
      "details": "Press Release regarding receipt of final approval by our Subsidiary Caplin Steriles Limited from USFDA for the Desmopressin Acetate Injection USP",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Caplin Point Laboratories Ltd has declared <strong>150%</strong> dividend, ex-date: 12 Sep 25",
          "dt": "2025-09-12",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Caplin Point Laboratories Ltd has announced <strong>2:10</strong> stock split, ex-date: 19 Oct 16",
          "dt": "2016-10-19",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views

Why is Caplin Point Laboratories Ltd falling/rising?

2026-03-24 01:31:08

Recent Price Movement and Market Context

Caplin Point Laboratories has been under pressure in the short term, with the stock losing 4.73% over the past week and 10.01% in the last month. Year-to-date, the stock has declined by 15.32%, slightly underperforming the benchmark Sensex, which fell 14.70% in the same period. Over the last year, the stock’s performance has been particularly weak, registering a 22.64% loss compared to the Sensex’s 5.47% decline. Despite this, the company’s longer-term returns remain impressive, with gains of 158.97% over three years and 264.20% over five years, significantly outpacing the benchmark indices.

On the day of the decline, the stock traded close to its 52-week low, just 0.52% above the lowest price of ₹1,551.05. Intraday, it touched ...

Read full news article
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Press Release / Media Release

13-Mar-2026 | Source : BSE

Press release regarding receipt of final approval by our subsidiary Caplin Steriles Limited from USFDA for the Potassium Phosphates Injection USP

Announcement under Regulation 30 (LODR)-Cessation

03-Mar-2026 | Source : BSE

Cessation of Dr. C K Gariyali as an Independent Director of the Company with effect from March 3 2026.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

28-Feb-2026 | Source : BSE

Press Release regarding receipt of final approval by our Subsidiary Caplin Steriles Limited from USFDA for the Desmopressin Acetate Injection USP

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Caplin Point Laboratories Ltd has declared 150% dividend, ex-date: 12 Sep 25

stock-summary
SPLITS

Caplin Point Laboratories Ltd has announced 2:10 stock split, ex-date: 19 Oct 16

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available